                         SEQUENCE LISTING

<110>  APREA THERAPEUTICS AB
 
<120>  COMBINATION TREATMENT WITH A P53 REACTIVATOR AND AN INHIBITOR OF 
       AN ANTIAPOPTOTIC BCL-2 FAMILY PROTEIN

<130>  21120495

<150>  US 62/902,214
<151>  2019-09-18

<150>  US 62/993,509
<151>  2020-03-23

<150>  US 63/028,477
<151>  2020-05-21

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered p53 activator peptide


<220>
<221>  LIPID
<222>  (1)..(1)
<223>  MYRISTATE

<400>  1

Arg Arg His Ser Thr Pro His Pro Asp 
1               5                   


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered p53 activator peptide

<400>  2

Arg Glu Asp Glu Asp Glu Ile Glu Trp 
1               5                   


<210>  3
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Engineered p53 binding aptamer

<400>  3
attagcgcat tttaacatag ggtgc                                             25


<210>  4
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered p53 activator peptide

<400>  4

Arg Arg Arg Arg Arg Arg Arg Arg Arg Leu Thr Arg Ile Thr Leu Glu 
1               5                   10                  15      


